Leveraging modular gene editors and new regulatory pathways, Aurora will develop and commercialize therapies that can be rapidly tailored to many rare variants -- Founded by CRISPR pioneers Jennifer ...

Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...

A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

Nkembuh, N. (2026) Symbiotic Communication Systems: Examining the Co-Evolution of Human-AI Communication Patterns in the ...

Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

There's a unique video game design curriculum at Culver City High School and it's already getting students jobs in the gaming ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...